Skip to main content
IMVT
NASDAQ Life Sciences

Immunovant Q2 Loss Narrows to $97.2M; $722.3M Cash Funds GD Launch

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$35.2
Mkt Cap
$6.306B
52W Low
$21.43
52W High
$45.42
52W Position info
64% above low
Off High info
23% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

IMVT sits 64% above its 52-week low of $21.43 on elevated volume (1.9× avg).

Summary

Immunovant's fiscal Q2 net loss narrowed to $97.2 million from $126.5 million a year ago, with $722.3 million in cash that management says funds operations to a potential Graves' disease launch. The 10-Q also discloses a September 2026 derivative suit over the Roivant private placement and the CTO's retirement effective around December 4, 2026.


Key Events · Earnings and Guidance · IMVT

  • Q2 Loss Narrows on Lower R&D

    Net loss was $97.2 million for the three months ended September 30, 2026, versus $126.5 million a year earlier, as R&D fell $29.2 million to $85.0 million on batoclimab wind-down and lower IMVT-1402 contract manufacturing costs.

  • Cash of $722.3M, Runway to GD Launch

    Cash and cash equivalents were $722.3 million at September 30, 2026, down from $902.1 million at March 31, 2026; management expects this to fund operations to a potential commercial launch of IMVT-1402 in Graves' disease.

  • Possible Development Expansion Not in Plan

    Following positive D2T RA results, Immunovant is evaluating additional late-stage development investment that is not reflected in the current operating plan and would prompt updated cash runway guidance.

  • Derivative Suit Over Roivant Placement

    A stockholder derivative action filed in September 2026 in Delaware Chancery names Roivant as controlling stockholder and certain current and former directors, alleging fiduciary breaches tied to the January 2025 private placement; the company says the claims are without merit and cannot estimate a loss.


Analysis · IMVT · Life Sciences

The quarter itself is the good news: the net loss fell to $97.2 million from $126.5 million a year ago as R&D dropped $29.2 million to $85.0 million, mostly from winding down batoclimab and lower contract manufacturing spend. Cash stands at $722.3 million, down from $902.1 million at March 31, and management says that funds operations to a potential Graves' disease launch — but it is now evaluating expanded late-stage development that is not in the current plan, which would shorten that runway and likely require new capital. Two items buried in the filing matter for governance: a stockholder derivative suit filed in September 2026 in Delaware Chancery over the January 2025 private placement with controlling holder Roivant, and the retirement of Chief Technology Officer Jay Stout effective around December 4, 2026. Neither is a thesis-changer on its own, but the suit targets the controlling stockholder relationship and the CTO exit removes technical leadership just as IMVT-1402 moves toward registrational filings.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IMVT was trading at $35.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $21.43 to $45.42. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMVT - Latest Insights

IMVT
Nov 09, 2026, 7:09 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $35.85
Real-time Price: $34.69 info
Change: -$1.16 (-3%) info
Market Cap: $6.306B info
IMVT
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $28.10
Real-time Price: $34.69 info
Change: +$6.59 (+23%) info
Market Cap: $6.306B info
IMVT
Nov 09, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $28.10
Real-time Price: $34.69 info
Change: +$6.59 (+23%) info
Market Cap: $6.306B info
IMVT
Sep 23, 2026, 7:01 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $36.20
Real-time Price: $34.69 info
Change: -$1.51 (-4%) info
Market Cap: $6.306B info
IMVT
Aug 07, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $39.74
Real-time Price: $34.69 info
Change: -$5.05 (-13%) info
Market Cap: $6.306B info